Department of Urology, Kyoto Prefectural University of Medicine, Kyoto City, Japan.
Low Urin Tract Symptoms. 2022 Sep;14(5):393-400. doi: 10.1111/luts.12457. Epub 2022 Jul 13.
This multicenter and prospective study was performed to evaluate the efficacy of tadalafil on patient-reported bother for each symptom in men with lower urinary tract symptoms (LUTS).
Men with LUTS received 5 mg of tadalafil daily for 4 weeks. We assessed change in symptom severity using both international prostate symptom score (IPSS), and overactive bladder symptom score (OABSS), as well as patient-reported quality of life (QOL: bother or satisfaction) for each symptoms using IPSS-visual analog scale (IPSS-VAS) and OABSS-VAS.
We found significant improvements in total IPSS (P < 0.001), including voiding symptoms (P < 0.001), storage symptoms (P < 0.001), and QOL (P < 0.001). All VAS measures corresponding to symptoms in IPSS and OABSS also significantly improved (P < 0.001). The most bothersome symptoms for each patient at baseline evaluated by VAS measures significantly improved (P < 0.001). Patients whose most bothersome symptoms at baseline included IPSS-Q7 (nocturia) showed significantly smaller improvement of VAS measure after treatment than those without it (P = 0.024).
Daily tadalafil significantly improved not only symptom severity of LUTS but also patient-reported QOL on each symptom.
本多中心前瞻性研究旨在评估他达拉非治疗男性下尿路症状（LUTS）患者各症状患者报告困扰的疗效。
LUTS 患者每日服用 5mg 他达拉非，共 4 周。我们使用国际前列腺症状评分（IPSS）和膀胱过度活动症症状评分（OABSS）评估症状严重程度的变化，同时使用 IPSS 视觉模拟评分（IPSS-VAS）和 OABSS-VAS 评估患者报告的每个症状的生活质量（困扰或满意度）。
我们发现总 IPSS（P<0.001），包括排尿症状（P<0.001）、储存症状（P<0.001）和 QOL（P<0.001）均有显著改善。所有与 IPSS 和 OABSS 相对应的 VAS 测量值也显著改善（P<0.001）。VAS 测量评估的每位患者的基线最困扰症状显著改善（P<0.001）。基线时最困扰症状包括 IPSS-Q7（夜尿症）的患者，治疗后 VAS 测量值的改善明显小于没有该症状的患者（P=0.024）。
每日他达拉非不仅显著改善了 LUTS 的症状严重程度，还改善了患者对每个症状的报告生活质量。
